Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A2 | O43868 | 11/20 | 0.51 |
| ▸ | HSPA8 | P11142 | 5/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.45 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3877828 | 0.92 | SLC28A2 (0.55) | SLC28A2HSPA8ADORA2AADORA2BHSPA5 | |
| SCHEMBL13855521 | 0.92 | SLC28A2 (0.55) | SLC28A2HSPA8ADORA2AADORA2BHSPA5 | |
| SCHEMBL3880076 | 0.85 | ADK (0.42) | SLC28A2HSPA8ADORA2AADORA2BMEN1 | |
| SCHEMBL13855522 | 0.85 | HSPA8 (0.60) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL13855561 | 0.81 | HSPA8 (0.48) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL4031221 | 0.80 | ADORA2A (0.50) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL13855562 | 0.79 | ADORA2A (0.49) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL3880247 | 0.78 | ADORA2A (0.48) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL4239470 | 0.78 | ADORA2A (0.48) | HSPA8ADORA2AADORA2BHSPA5FBP1 | |
| SCHEMBL4239465 | 0.78 | ADORA2A (0.48) | HSPA8ADORA2AADORA2BHSPA5FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2007113538-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | ASTRAZENECA AB (SE) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118220-A1 | SUBSTITUTED ADENINES AND THE USES THEREOF | HPRT1, APRT, NUDT1 | SLC28A2 61/4885HSPA8 4053/4885ADORA2A 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.